Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02866747
Recruitment Status : Recruiting
First Posted : August 15, 2016
Last Update Posted : July 7, 2020
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Institut Claudius Regaud

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024